FGFR2 and urinary bladder cancer: Inhibition of FGFR family members by ponatinib has been demonstrated in preclinical models of endometrial cancers with FGFR2 mutations, bladder cancers with FGFR3 mutations, as well as breast, lung, and colon cancer cell lines harboring amplification of the FGFR1 or FGFR2 gene [16].